Verdezyne is a technology company.
Verdezyne has raised $69.0M across 5 funding rounds.
Verdezyne has raised $69.0M in total across 5 funding rounds.
Verdezyne has raised $69.0M in total across 5 funding rounds.
Verdezyne's investors include Bold Capital Partners.
High-level overview — Verdezyne is an industrial biotechnology company that engineers proprietary yeast fermentation platforms to produce renewable chemical intermediates (notably dicarboxylic acids such as dodecanedioic acid and adipic and sebacic acids) as sustainable alternatives to petroleum-derived chemicals used in nylons, coatings, lubricants and other industrial products[1][5]. Verdezyne’s technology is feedstock‑flexible (able to use sugars, plant oils and by‑products) and aims to lower greenhouse‑gas emissions and manufacturing hazards while meeting industry quality specifications for commodity chemical building blocks[1][2][3].
Origin story — Verdezyne was formed in the early 2010s to commercialize engineered‑yeast routes to renewable chemicals, building a team of scientists from biotech and chemical industries and moving from concept through pilot demonstration and early pilot production of DDDA and sebacic acid[2]. The company’s platform grew out of metabolic engineering work (including directed evolution approaches and a xylose isomerase technology) that allowed yeast to convert various renewable feedstocks into medium‑ and long‑chain dicarboxylic acids; portions of that technology (xylose isomerase) were later acquired by DuPont Industrial Biosciences[4][6]. Verdezyne’s fermentation process and BIOLON™ DDDA product earned recognition such as the U.S. EPA Presidential Green Chemistry Challenge Small Business Award and USDA Certified Biobased labeling after demonstration-scale production (over 70,000 pounds produced during scale‑up)[1][2].
Core differentiators
Role in the broader tech and industrial landscape — Verdezyne is positioned at the intersection of industrial biotechnology and the decarbonization of chemical supply chains, riding the trend toward bio‑based alternatives to petrochemicals and circular feedstock strategies[1][3]. Timing matters because demand for lower‑carbon, renewable chemical inputs is rising across polymers, adhesives, coatings and specialty chemicals, and feedstock flexibility helps mitigate volatility in agricultural and oil markets[3]. By proving a route to renewable nylon intermediates and other dicarboxylic acids, Verdezyne contributes to diversifying supply, lowering lifecycle emissions of materials, and demonstrating that fermentation‑based routes can meet commodity specifications—which influences buyers, downstream polymer makers, and investors in bio‑industrial scale‑ups[1][2][5].
Quick take & future outlook — Verdezyne’s near‑term trajectory centers on scaling commercial production of its flagship DDDA and related acids and continuing to commercialize feedstock‑flexible, cost‑competitive fermentation routes for large‑volume chemical intermediates[1][2][5]. Trends that will shape its path include increasing corporate and regulatory pressure for lower‑carbon materials, improvements in industrial fermentation and downstream separations (lowering CAPEX/OPEX), and strategic partnerships or technology acquisitions by larger chemical firms (as seen with the sale of specific technologies to DuPont)[6]. If Verdezyne secures commercial‑scale plants and consistent offtake from polymer and specialty chemical manufacturers, it can materially influence the decarbonization of certain nylon and specialty markets by supplying bio‑based intermediates that meet existing industry specs[1][2][5].
Verdezyne has raised $69.0M across 5 funding rounds. Most recently, it raised $48.0M Venture Round in March 2014.
| Date | Round | Lead Investors | Other Investors |
|---|---|---|---|
| Mar 1, 2014 | $48.0M Venture Round | Bold Capital Partners | |
| Feb 1, 2010 | $9.0M Venture Round | Bold Capital Partners | |
| Nov 1, 2009 | $3.0M Venture Round | Bold Capital Partners | |
| Jul 1, 2007 | $7.0M Series C | Bold Capital Partners | |
| Feb 1, 2006 | $2.0M Series B | Bold Capital Partners |